Exigent Capital

RenalGuard Solutions, Inc. specializes in manufacturing medical devices aimed at the cardiac and vascular markets. Its flagship product, RenalGuard, is designed to remove contrast dyes that can be harmful to the kidneys in at-risk patients undergoing specific imaging procedures. The company offers RenalGuard Therapy, which mitigates the toxic effects of contrast media, potentially decreasing the incidence of contrast-induced nephropathy (CIN). The RenalGuard System includes a console and a single-use set for infusion and urine collection. RenalGuard is already approved for sale in the European Union for general fluid balancing and has shown effectiveness in preventing CIN in two European studies. Additionally, it is currently undergoing a pivotal trial in the United States as part of the FDA approval process. RenalGuard Solutions distributes its products through a network of distributors both domestically and internationally, and it is headquartered in Milford, Massachusetts.

MaxQ-AI utilizes advanced cognitive analytics and artificial intelligence to deliver real time decision support tools to improve clinical outcomes in acute medical scenarios. The MaxQ team of artificial intelligence, machine learning, deep learning and algorithmic experts and its medical advisory boards in Israel and the United States are achieving breakthroughs in standards of cost and care.

RenalGuard Solutions, Inc. specializes in manufacturing medical devices aimed at the cardiac and vascular markets. Its flagship product, RenalGuard, is designed to remove contrast dyes that can be harmful to the kidneys in at-risk patients undergoing specific imaging procedures. The company offers RenalGuard Therapy, which mitigates the toxic effects of contrast media, potentially decreasing the incidence of contrast-induced nephropathy (CIN). The RenalGuard System includes a console and a single-use set for infusion and urine collection. RenalGuard is already approved for sale in the European Union for general fluid balancing and has shown effectiveness in preventing CIN in two European studies. Additionally, it is currently undergoing a pivotal trial in the United States as part of the FDA approval process. RenalGuard Solutions distributes its products through a network of distributors both domestically and internationally, and it is headquartered in Milford, Massachusetts.

StorePower Inc. is a Chicago-based company that provides an online supermarket platform designed to streamline the grocery shopping experience. Established in 2015 as a subsidiary of Direct Eats, Inc., StorePower offers a comprehensive range of services through its Software as a Service (SaaS) model. The platform facilitates various aspects of online retailing, including picking, packing, payment processing, click-and-collect options, and delivery management. Additionally, StorePower's system features automatic stock updates and data analysis tools that help grocery chains optimize their online operations and better understand shopping traffic. With its focus on creating efficient and customized solutions, StorePower aims to enhance the online grocery shopping experience for both retailers and consumers.

Revelator Limited provides comprehensive business and marketing cloud solutions tailored for music professionals, including independent artists and record labels. Founded in 2013 and headquartered in Jerusalem, Israel, the company offers a platform that integrates various functions such as sales, marketing, accounting, and analytics into a single system. Revelator's technology supports catalog management, metadata handling, distribution, reporting, royalty management, and business intelligence. By leveraging artificial intelligence and machine learning, the company facilitates the transition from traditional music intellectual property to digital assets. This innovation enables automated workflows for royalty forecasting, settlement, and payment, helping clients to lower costs, reduce risks, and efficiently manage rights administration and royalty distribution.

ImmunArray, founded in 2006, is a molecular diagnostics company specializing in the development of innovative tests for autoimmune and neurologic diseases. The company has created a proprietary test designed to accurately rule out lupus, an autoimmune disease that is often challenging to diagnose and can be confused with other conditions. This test enables healthcare providers to avoid incorrect diagnoses and inappropriate treatments. Additionally, ImmunArray develops in-vitro molecular diagnostics systems that utilize microarray technology and informatics to profile patients' immune systems. Their multi-analyte biomarker-based tests provide valuable insights for the detection of autoimmune diseases, lung cancer, and other health issues, aiding physicians in their decision-making processes.

Liberty SBF is a commercial real estate finance company that specializes in small-balance commercial lending, catering to the financing needs of small businesses navigating a difficult credit landscape. The company offers a range of loan products, including conventional, CMBS, and government-guaranteed options, aimed at helping borrowers acquire commercial real estate and other assets. With a focus on providing flexible and customized loan solutions, Liberty SBF enables businesses to secure low-cost financing for both commercial properties and working capital. The company's streamlined online application process ensures that clients can access funding quickly and transparently, facilitating their growth and investment objectives.

MaxQ-AI utilizes advanced cognitive analytics and artificial intelligence to deliver real time decision support tools to improve clinical outcomes in acute medical scenarios. The MaxQ team of artificial intelligence, machine learning, deep learning and algorithmic experts and its medical advisory boards in Israel and the United States are achieving breakthroughs in standards of cost and care.